Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 8, 2007, Pages 719-723

  Müssig, Karsten ^a,c   Petersenn, Stephan ^b   Wehrmann, Manfred ^c   Horger, Marius ^c   Vierling, Peter ^d   Häring, Hans Ulrich ^a   Gallwitz, Baptist ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Department of Trauma Surgery   (Germany)

Author keywords

Humoral hypercalcaemia; Neuroendocrine tumour; Octreotide; Pancreas; Parathyroid hormone related peptide; Somatostatin receptors

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; CONTRAST MEDIUM; DIURETIC AGENT; FUROSEMIDE; OCTREOTIDE; OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 68]; PARATHYROID HORMONE RELATED PROTEIN; PREDNISOLONE; SODIUM CHLORIDE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CONSTIPATION; DIARRHEA; ENDOCRINE TUMOR; EPIGASTRIC PAIN; FATIGUE; GASTRITIS; GASTROSCOPY; HEMODIALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LIVER BIOPSY; LIVER METASTASIS; MALE; NAUSEA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; VOMITING; WEIGHT REDUCTION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, NEUROENDOCRINE; HUMANS; HYPERCALCEMIA; MALE; OCTREOTIDE; PANCREATIC NEOPLASMS; PARANEOPLASTIC SYNDROMES; PARATHYROID HORMONE-RELATED PROTEIN; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34447569326     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000223908.00987.18     Document Type: Article

References (25)

1. Strewler GJ. The parathyroid hormone-related protein. Endocrinol Metab Clin North Am 2000; 29:629-645.
2. Wynick D, Ratcliffe WA, Heath DA, Ball S, Barnard M, Bloom SR. Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone related protein. BMJ 1990; 300:1314-1315.
3. Rizzoli R, Sappino AP, Bonjour JP. Parathyroid hormone-related protein and hypercalcemia in pancreatic neuro-endocrine tumors. Int J Cancer 1990; 46:394-398.
4. Mitlak BH, Hutchison JS, Kaufman SD, Nussbaum SR. Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas. Horm Metab Res 1991; 23:344-346.
5. Miraliakbari BA, Asa SL, Boudreau SF. Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Hum Pathol 1992; 23:884-887.
6. Ratcliffe WA, Bowden SJ, Dunne FP, Hughes S, Emly JF, Baker JT, et al. Expression and processing of parathyroid hormone-related protein in a pancreatic endocrine cell tumour associated with hypercalcaemia. Clin Endocrinol (Oxf) 1994; 40:679-686.
7. Anthony LB, May ME, Oates JA. Case report: lanreotide in the management of hypercalcemia of malignancy. Am J Med Sci 1995; 309:312-314.
8. Mao C, Carter P, Schaefer P, Zhu L, Dominguez JM, Hanson DJ, et al. Malignant islet cell tumor associated with hypercalcemia. Surgery 1995; 117:37-40.
9. Geoghegan JG, Howerton R, Ratcliffe WA, Williamson RC. Double hormone syndromes in two pancreatic neuroendocrine tumours. HPB Surg 1996; 9:261-263.
10. Wu TJ, Lin CL, Taylor RL, Kvols LK, Kao PC. Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma. Mayo Clin Proc 1997; 72:1111-1115.
11. van de Loosdrecht AA, van Bodegraven AA, Sepers JM, Sindram JW. Long-term followup of two patients with metastatic neuroendocrine tumours treated with octreotide. Neth J Med 1998; 53:118-123.
12. Clemens P, Gregor M, Lamberts R. Pancreatic neuroendocrine tumor with extensive vascularisation and parathyroid hormone-related protein (PTHrP)-associated hypercalcemia of malignancy. Exp Clin Endocrinol Diabetes 2001; 109:378-385.
13. Abraham P, Ralston SH, Hewison M, Fraser WD, Bevan JS. Presentation of a PTHrP-secreting pancreatic neuroendocrine tumour, with hypercalcaemic crisis, pre-eclampsia, and renal failure. Postgrad Med J 2002; 78:752-753.
14. deHerder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003; 10:451-458.
15. Öberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15:966-973.
16. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med 2000; 44:13-21.
17. Mantzoros CS, Suya LJ, Moses AC, Spark R. Intractable hypercalcaemia due to parathyroid hormone-related peptide secretion by a carcinoid tumour. Clin Endocrinol (Oxf) 1997; 46:373-375.
18. Barhoum M, Hutchins L, Fonseca VA. Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide. Am J Med Sci 1999; 318:203-205.
19. Harrison M, James N, Broadley K, Bloom SR, Armour R, Wimalawansa S, et al. Somatostatin analogue treatment for malignant hypercalcaemia. BMJ 1990; 300:1313-1314.
20. delaMata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995; 95:2846-2852.
21. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24:28-47.
22. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 2000; 85:3882-3891.
23. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005; 32:478-485.
24. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherubl H, et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996; 38:33-39.
25. Froidevaux S, Hintermann E, Torok M, Macke HR, Beglinger C, Eberle AN. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 1999; 59:3652-3657.